New regimen prevents TB in 12 weekly doses

This article is more than 13 years old. Click here for more recent articles on this topic

A large trial has shown that a 12-week course of combination treatment for latent tuberculosis is just as effective as a nine-month course of isoniazid in countries with a low to moderate burden of TB, with the additional advantage that the new regimen can be dosed once a week.

The findings, from the Prevent TB study, were presented this week at the American Thoracic Society’s International Conference in Denver.

However, the applicability of the findings for people with HIV and for settings with a high burden of TB is unclear, and more research will be needed.

Glossary

isoniazid

An antibiotic that works by stopping the growth of bacteria. It is used with other medications to treat active tuberculosis (TB) infections, and on its own to prevent active TB in people who may be infected with the bacteria without showing any symptoms (latent TB). 

latent TB

A form of TB that is not active. Persons with latent TB are infected with M. tuberculosis but do not have any symptoms and they cannot spread TB infection to others. Only specific tests will tell if anyone has latent TB. Treatment for latent TB is recommended in people living with HIV. 

active TB

Active disease caused by Mycobacterium tuberculosis, as evidenced by a confirmatory culture, or, in the absence of culture, suggestive clinical symptoms.

nucleoside

A precursor to a building block of DNA or RNA. Nucleosides must be chemically changed into nucleotides before they can be used to make DNA or RNA. 

immune system

The body's mechanisms for fighting infections and eradicating dysfunctional cells.

Latent tuberculosis (TB) is an infection with TB that has been contained by the immune system, does not cause symptoms and cannot be passed on to other people. Latent TB may develop into active TB if the immune system weakens due to malnutrition or HIV infection, for example.

Preventive treatment with a six- to nine-month course of the antibiotic isoniazid reduces the risk of developing active TB by between 30 and 60%, but the six- to nine-month course of daily isoniazid may be difficult for patients to take.

As a result there has been interest in determining whether it is possible to shorten the course of TB preventive treatment.

The Prevent TB trial was designed more than ten years ago, to compare:

  • 12 weeks of treatment with a once-weekly regimen that combined isoniazid (900mg tablet) with a new anti-TB drug rifapentine (900mg in six 150mg tablets), given as directly observed treatment.
  • Standard TB preventive TB treatment with nine months of self-administered isoniazid (300mg once daily), the recommended preventive regimen in the United States.

The trial recruited 8053 participants in the United States, Canada, Brazil and Spain, but excluded participants with HIV infection who were taking antiretroviral drugs, due to drug interactions between rifapentine and HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors.

Participants were randomised to the experimental regimen or to standard treatment, and followed for 33 months after enrolment to assess the effect on development of active TB and survival, as well as adherence and side-effects.

The new regimen was associated with fewer cases of active TB (7 versus 15 in the standard treatment arm) and better adherence (82 vs 69% completed the course of treatment).

“Although the standard regimen is very effective in treating latent TB infection, ensuring that those who need treatment both begin and complete the lengthy, cumbersome isoniazid regimen is challenging,” said CDC Director Thomas R Frieden, MD.  “New, simpler ways to prevent TB disease are urgently needed, and this breakthrough represents one of the biggest developments in TB treatment in decades.”

In the light of these results, new US guidelines on TB preventive treatment are expected before the end of the year.

Further research will be needed in countries with a high burden of TB, and in people with HIV.

References

Sterling T et al. PREVENT TB: Results of a 12-dose, once-weekly treatment of latent tuberculosis infection (LTI). American Thoracic Society International Conference, oral presentation, 16 May 2011